Modified R-DAOx as salvage therapy in patients with relapsed or refractory diffuse large B-cell lymphoma

被引：0
|
作者：
Rigacci, L. [1 ]
Fabbri, A. [2 ]
Mappa, S. [1 ]
Nassi, L. [1 ]
Lenoci, M. [2 ]
Puccini, B. [1 ]
Alterini, R. [1 ]
Chitarrelli, I [2 ]
Carrai, V [1 ]
Lauria, F. [2 ]
Bosi, A. [1 ]
机构：
[1] Univ Florence, Florence Azienda Osped, Dept Hematol, I-50121 Florence, Italy
[2] Univ Siena, Siena Azienda Osped, Dept Hematol, I-53100 Siena, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [31] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Gatwood, Justin
    Masaquel, Anthony
    Ross, Ryan
    Sheinson, Danny
    Hossain, Farah
    Li, Jia
    James, Cameron
    Fox, David
    [J]. BLOOD, 2022, 140 : 7906 - 7907
  • [32] Bendamustine/rituximab in relapsed or refractory diffuse large B-cell lymphoma
    Vacirca, J. L.
    Acs, P. I.
    Shimkus, B. J.
    Rosen, P. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [33] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [34] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
  • [35] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [36] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
    Ren, Liangliang
    Li, Ling
    Zhang, Lei
    Li, Xin
    Fu, Xiaorui
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Yan, Jiaqin
    Kong, Fei
    Zhang, Mingzhi
    [J]. INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2022, 38 (01) : 42 - 50
  • [37] A prognostic nomogram constructed for relapsed or refractory diffuse large B-cell lymphoma patients
    Jiang, Shiyu
    Qin, Yan
    Liu, Peng
    Yang, Jianliang
    Yang, Sheng
    He, Xiaohui
    Zhou, Shengyu
    Gui, Lin
    Zhang, Changgong
    Zhou, Liqiang
    Sun, Yan
    Shi, Yuankai
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (02) : E11 - E16
  • [38] DeVIC chemotherapy is effective for patients with refractory or relapsed diffuse large B-cell lymphoma
    Okada, Kazuya
    Sakai, Kazuya
    Muranushi, Hiroyuki
    Okamoto, Yusuke
    Sugiura, Hiroyuki
    Sato, Aki
    Sato, Takayuki
    Maeda, Takeshi
    Onishi, Tatsuhito
    Ueda, Yasunori
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 108 - 108
  • [39] Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study
    Liangliang Ren
    Ling Li
    Lei Zhang
    Xin Li
    Xiaorui Fu
    Xinhua Wang
    Jingjing Wu
    Zhenchang Sun
    Xiaoyan Feng
    Yu Chang
    Zhiyuan Zhou
    Feifei Nan
    Jiaqin Yan
    Fei Kong
    Mingzhi Zhang
    [J]. Indian Journal of Hematology and Blood Transfusion, 2022, 38 : 42 - 50
  • [40] Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
    Galaznik, Aaron
    Huelin, Rachel
    Stokes, Michael
    Guo, Yelan
    Hoog, Meredith
    Bhagnani, Tarun
    Bell, Jill
    Shou, Yaping
    [J]. FUTURE SCIENCE OA, 2018, 4 (07):
12345